RSV is a leading cause of pneumonia in the elderly.
European regulators have approved the region's first vaccine for respiratory syncytial virus (RSV), which causes thousands of hospitalisations and deaths annually.
The shot, called Arexvy, is made by British drugmaker GSK and is designed to protect people aged 60 and over.
RSV typically causes cold-like symptoms, but is a leading cause of pneumonia in toddlers and the elderly.
The complex molecular structure of the virus and safety concerns with previous vaccine attempts had stymied efforts to successfully develop a shot since the virus was first discovered in 1956.
The approval this morning by the European Commission, which follows a recent endorsement from the European Medicines Agency, comes about a month after the US health regulator the gave Arexvy the green light.
The availability of the vaccine in Europe will depend on national recommendations and reimbursement discussions, but the first launches are expected this autumn ahead of the 2023/2024 RSV season, GSK said in a statement.
The company said it does not expect a significant rollout in Europe this year
Ticketmaster Contest Consumer Law Breach Accusations In District Court
Irish Rail Fires Firm Behind Abandoned €50 Million IT System
Energy Regulator Proposes Lower Gas Rates For Data Centres
First Day Of FF's Political Think In Takes Place In Offaly
Kildare Councillor Criticises Lack Of Investment As Public Transport Costs Rise
Former APCOA Employee Claims Staff Were Paid Commission Based On The Number Of Vehicles They Clamped
EU Ministers Meeting Across Dublin And Kildare This Week
Teenager Dies On E-Scooter Following Collision On Clare-Limerick Border
